abs2.txt	purpose		the	primary	objective	of	this	study	was	to	determine	recommendeddose	vascular	disrupting	agent	bnc105p	in	combination	with	gemcitabineand	carboplatin	patients	ovarian	cancer	first	or	second	relapse	aminimum	4	month	progression-free	interval	after	last	platinum	methods	received	auc4	on	day	1	withescalating	doses	800	1000	mg/m2	gemcitabine	days	and	8	escalatingdoses	12	16	2	9	every	21	for	a	maximum	forsix	cycles	maintenance	treatment	continued	amaximum	six	additional	were	followed	safety	andanti-tumor	activity	results	fifteen	enrolled	adverse	events	mostcommonly	hematological	origin	dose-limiting	toxicities	(thrombocytopenia	andneutropenia)	occurred	two	at	dose	level	no	observedat	as	single	well	tolerated	maintenancetreatment	ten	(67%)	achieved	complete	partial	response	accordingto	ca125	and/or	recist	criteria	four	13	(31%)	responded	by	recistalone	median	survival	5	months	conclusions	we	have	established	that	gemcitabine1000	is	recommended	has	anacceptable	toxicity	profile	further	exploration	cancersetting	planned
